TFX

Teleflex Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray

Retrieved on: 
Jeudi, mai 9, 2024
Corporation, FDA, TFX, Research, Workflow, IO, Health, Emergency medicine, Vascular access, Medical imaging

WAYNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies and pioneer in intraosseous vascular access, today announced the launch of the Arrow™ EZ-IO™ Intraosseous Access Procedure Tray.

Key Points: 
  • WAYNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies and pioneer in intraosseous vascular access, today announced the launch of the Arrow™ EZ-IO™ Intraosseous Access Procedure Tray.
  • This sterile, single-use tray includes all the components required for the IO access procedure, enabling a streamlined clinician workflow.
  • The tray is packaged with an Arrow™ EZ-IO™ Intraosseous Needle Set (15mm, 25mm, or 45mm), which is designed to help ensure a fast,1 precise, and steady insertion.
  • “The new Arrow™ EZ-IO™ Procedure Tray was designed to optimize efficiency in gaining fast vascular access while increasing the accessibility of the EZ-IO™ System,” said Kevin Robinson, President and General Manager of Anesthesia and Emergency Medicine, Teleflex.

Outcomes From Two New Head-to-Head Randomized Controlled Trials Involving the UroLift™ System Highlight a Superior Patient Experience* Against Rezūm and Its Advantage Over Medical Therapy as an Early Intervention for BPH

Retrieved on: 
Mardi, mai 7, 2024
IMPACT, FDA, Teleflex, Urology, Prostate, PVP, PUL, LUTS, Heat, TFX, MD, TURP, Research, Mars, Prostatic urethral lift, Patient, Physician, Medicine, Urethra, AUA, ATC, Database, Patient satisfaction, Quality of life, BPH

“For over 10 years, Teleflex has advanced BPH research through numerous trials involving the UroLift™ system and now other contemporary treatments.

Key Points: 
  • “For over 10 years, Teleflex has advanced BPH research through numerous trials involving the UroLift™ system and now other contemporary treatments.
  • ***5
    Once procedure volume is factored in, the UroLift™ System has the lowest rates of mild, moderate, and severe postoperative complications on a per case basis from 2019 to 2022 in the MAUDE database.
  • The goal is for the provider and patient to decide whether to continue, stop, or switch to another therapy based on the symptomatic response of medication.
  • **9 It is the only leading enlarged prostate procedure that does not require heating, cutting, or destruction of prostate tissue.10-11
    For more information about the UroLift™ System, visit www.UroLift.com .

Teleflex Announces Quarterly Dividend

Retrieved on: 
Lundi, mai 6, 2024
Teleflex, TFX

WAYNE, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock.

Key Points: 
  • WAYNE, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock.
  • The dividend is payable June 14, 2024, to shareholders of record at the close of business on May 15, 2024.
  • Additional information about Teleflex can be obtained from the company’s website at teleflex.com .

Teleflex Announces First Quarter 2024 Earnings Conference Call Information

Retrieved on: 
Jeudi, avril 18, 2024
Teleflex, ID, TFX, Telephone

WAYNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 2, 2024.

Key Points: 
  • WAYNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 2, 2024.
  • To participate in the conference call, please utilize this link to pre-register and receive the dial-in information.
  • An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 2, 2024, either on the Teleflex website or by telephone.
  • The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations).

Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types

Retrieved on: 
Mardi, avril 2, 2024
Urology, TFX, Development, Anatomy, ATC, Patient, Research and development, BPH, FDA, Physician, Medical imaging

The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significant advancement in BPH care.

Key Points: 
  • The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significant advancement in BPH care.
  • Bringing the enhanced tissue control capabilities onto the innovative and proven UroLift™ 2 platform allows me to deliver unparalleled precision to treat a broad spectrum of patients and anatomies.
  • It has transformed my approach to BPH care,” said Dr. Adam Craig Thomas of Parkview Physicians Group Urology in Fort Wayne, Indiana.
  • It ensures I’m always equipped to treat a broad range of patients with unique prostate types and anatomies.”
    To learn more about UroLift™ 2 ATC, visit UroLift.com .

Teleflex’s Climate Targets Validated by the Science Based Targets Initiative

Retrieved on: 
Jeudi, mars 28, 2024
TFX, Climate change, Science Based Targets initiative, Environment, GHG, Patient, Travel, Science, Climate, Corporate social responsibility, Ambition, Targets, Renewable energy

WAYNE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced its near- and long-term climate change targets have been validated by the Science Based Targets initiative (SBTi).

Key Points: 
  • WAYNE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced its near- and long-term climate change targets have been validated by the Science Based Targets initiative (SBTi).
  • The announcement comes ahead of the company’s release of its 2023 Global Impact Report, which will be published in May 2024.
  • Teleflex has responded to the SBTi’s urgent call for corporate climate action by committing to align with 1.5°C and net-zero through the Business Ambition for 1.5°C campaign.
  • Through the establishment and validation of the near-and long-term science-based emissions targets, Teleflex has committed to reaching net-zero greenhouse gas emissions (GHG) across its value chain by 2050.

Glancy Prongay & Murray LLP Announces Investigation of Teleflex Incorporated (TFX)

Retrieved on: 
Jeudi, mars 14, 2024
Class Action Lawsuit, Professional Services, Legal, Teleflex, GPM, TFX, Helmsley Building, Suite

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Teleflex Incorporated (NYSE: TFX) concerning the Company and its directors’ and officers’ possible violations of state laws.

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Teleflex Incorporated (NYSE: TFX) concerning the Company and its directors’ and officers’ possible violations of state laws.
  • If you inquire by email please include your mailing address, telephone number, and the number of shares purchased and held.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240314529066/en/

Lowey Dannenberg, P.C. Announces an Additional Settlement for Those Who Have Transacted in Euroyen-Based Derivatives Between January 1, 2006 through June 30, 2011

Retrieved on: 
Jeudi, mars 21, 2024
Barclays, J. P. Morgan, Agreement, Hearing, JPMorgan Chase, E pluribus unum, HSBC (United Kingdom), HSBC Bank, HSBC, American Bankers Association, Bank, TP ICAP, Chase Bank, Singapore Exchange, UBS AG, Sumitomo Mitsui Banking Corporation, Class, Lawyer, Interbank, Citibank, National Association, Person, Citigroup, Fairness, Tokyo Financial Exchange, Negotiation, GBD, Mitsubishi Group, District court, UBS, Defendant, Vexatious litigation, Knowledge, Settlement, Resona Holdings, TP, Norinchukin Bank, Shinkin Central Bank, TFX, Prior, Government, Société Générale, Plaintiff, Notice, CME, Conspiracy theory, Chicago Mercantile Exchange, ICAP, Court

The Settlement will provide an additional $35,000,000 to pay claims from persons who transacted in Euroyen-Based Derivatives from January 1, 2006 through June 30, 2011, inclusive.

Key Points: 
  • The Settlement will provide an additional $35,000,000 to pay claims from persons who transacted in Euroyen-Based Derivatives from January 1, 2006 through June 30, 2011, inclusive.
  • Before any money is paid, the Court will hold a Fairness Hearing to decide whether to approve the Settlement.
  • Contact your brokerage firm to see if you purchased, sold, held, traded, or otherwise had any interest in Euroyen-Based Derivatives.
  • These payments will also be deducted from the Settlement Fund before any distributions are made to the Settlement Class.

Teleflex Announces Quarterly Dividend

Retrieved on: 
Jeudi, février 22, 2024
TFX, Teleflex

WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock.

Key Points: 
  • WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock.
  • The dividend is payable March 15, 2024, to shareholders of record at the close of business on March 1, 2024.
  • Additional information about Teleflex can be obtained from the company’s website at teleflex.com .

Teleflex to Present at the 45th Annual Raymond James Institutional Investors Conference

Retrieved on: 
Mardi, février 20, 2024
TFX, Teleflex, Conference

WAYNE, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 45th Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, March 5, 2024, at 1:40 p.m. (ET).

Key Points: 
  • WAYNE, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 45th Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, March 5, 2024, at 1:40 p.m. (ET).
  • A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at teleflex.com .